Programs and initiatives

The following programs and initiatives are built to realize the Institute’s ambitious plans and to ensure OICR’s research will be translated to results for patients. To better understand how these programs and initiatives fit together, read about our strategy here.

Jump to: Technology Programs | Translational Research Initiatives | Global Leadership in Precision Oncology
| Collaborative Research Networks | Programs from the 2010-2015 Strategic Plan

Technology Programs

Diagnostic Development

The Diagnostic Development Program's mission is to initiate, disseminate and nurture expertise in the development of diagnostic assays and support the rapid implementation of precision medicine.

More details →

Drug Discovery

The Drug Discovery Program helps efficiently translate discoveries made in Ontario’s labs into novel oncology therapies.

More details →


The Genomics Program provides large-scale, next generation sequencing cancer genomics capabilities to researchers in Ontario and beyond.

More details →


The Imaging Program accelerates translation of research findings and developments of new imaging techniques and probes of cancer into clinical practice.

More details →


The Informatics Program develops new algorithms, software, databases, visualization tools and other necessary components to interpret the large and complex datasets being generated by OICR’s cancer research programs.

More details →

Translational Research Initiatives


PanCuRx seeks solutions to the high fatality rate of pancreatic cancer by generating new knowledge about genetic and biologic subsets of disease, mechanisms of tumorigenesis and tailored treatment options.

More details →

Global Leadership in Precision Oncology

Global Alliance for Genomics and Health

The Global Alliance for Genomics and Health (GA4GH) was formed to help accelerate the potential of genomic medicine to advance human health.

More details →

International Cancer Genome Consortium / International Cancer Genome Consortium for Medicine

The goal of the ICGC is to generate comprehensive catalogues of genomic abnormalities in tumours from 50 different cancer types.

More details →


Ontario-wide Cancer TArgeted Nucleic acid Evaluation (OCTANE) is a new OICR-supported initiative that provides next generation sequencing-based molecular profiling at multiple Ontario cancer centres.

More details →

Translational Genomics Laboratory

The Transformative Genomics Laboratory was built to fulfill an unmet need and further the use of genomics technologies in the clinical oncology space.

More details →

Collaborative Research Networks

Health Services Research Network

The Health Services Research Network provides the knowledge needed to optimize the delivery of cancer services today and to ensure appropriate dissemination of health service innovations and well-evaluated technologies

More details →

Ontario Molecular Pathology Research Network

The Ontario Molecular Pathology Research Network is a province-wide network of pathologists collaborating to carry out high-quality cancer research with a clear potential for clinical impact.

More details →

Ontario Tumour Bank

The Ontario Tumour Bank is a province-wide biorepository and data bank focused on collection of tumour-related human biospecimens.

More details →

Ontario Health Study

The Ontario Health Study is a landmark study with over 230,000 participants that will help researchers better understand the environmental, lifestyle, and genetic factors that cause cancer and other chronic diseases.

More details →

Canadian Cancer Clinical Trials Network

The Canadian Cancer Clinical Trials Network is a pan-Canadian initiative to improve the efficiency and quality of clinical trials in Canada.

More details →

Ontario Cancer Research Ethics Board

The Ontario Cancer Research Ethics Board is an expert central oncology REB serving almost every hospital in Ontario that conducts cancer clinical trials.

More details →

Programs from the 2010-2015 Strategic Plan

Cancer Stem Cell

The Cancer Stem Cell Program is determining whether cancer stem cells are clinically relevant by expanding the knowledge of tumour-initiating cells in several types of cancer.

More details →


The Ontario Regional BioTherapeutics (ORBiT) Program's mandate is to coordinate and drive the clinical testing and translation of promising anti-cancer biotherapies.

More details →

Innovation in Target Validation

The Innovation in Target Validation Program is developing and deploying innovative technologies in aid of cancer target discovery and validation.

More details →